Epitel, Inc.
PrivateLast Round
Series B
Jul 28, 2026
Est. Valuation
$88M
Total Funding Raised
$53.6M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Epitel, Inc. operates in Healthcare & Life Sciences and is based in Salt Lake City, Utah. Its latest recorded funding round was a Series B round in July 2026.
Epitel, Inc. is a digital health company that develops and commercializes wearable, wireless electroencephalogram (EEG) monitoring technology for seizure detection.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Health IoT, Vertical SaaS
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Epitel, Inc. Comparables
Compare Epitel, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Zeto, Inc. | 91% | |
| Ceribell | 80% | |
| NeuroServo | 79% |
For institutional investors. Book with your work email.
Epitel, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 28, 2026 | ||||
| Series A | Feb 16, 2022 | ||||
| Grant | Feb 15, 2022 | ||||
| Seed | Dec 16, 2019 | ||||
| Grant | Jan 25, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Epitel, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ideaship | Seed |
| NIH RADx | Grant |
| OSF Ventures | Series A |
| Dexcom Ventures | Series A |
| Genoa Ventures | Series B, Series A |
| Wavemaker Three-Sixty Health | Series A |
| Epilepsy Foundation | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors increased 110% MoM.
- Aug 21, 2026
Monthly visitors grew 106% MoM, reaching 6K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 13, 2026
Epitel appoints Melissa Farina as its first Chief Financial Officer on Oct 13th '26 in Utah, where she leads financial strategy and operations following the company’s Series B financing.
- hiresSep 30, 2026
Epitel appoints James Reinstein as Chair of the Board as the company enters its next stage of growth in Utah on Oct 13th '26.
For institutional investors. Book with your work email.
Epitel, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Epitel, Inc.'s valuation, stock price, and market status.
Is Epitel, Inc. a public or private company?
Epitel, Inc. is a private company.
What is the current stock price of Epitel, Inc.?
Epitel, Inc. is a private company, so its shares have no public market price. Caplight tracks Epitel, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Epitel, Inc. worth (valuation)?
Epitel, Inc.'s valuation is estimated at $88.0M based on funding round data.
Can I buy Epitel, Inc. stock?
Epitel, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Epitel, Inc.'s last funding round?
Epitel, Inc.'s most recent funding round was Series B on July 28, 2026.
Who are the main investors in Epitel, Inc.?
Key investors in Epitel, Inc. include Ideaship, Genoa Ventures, Catalyst Health Ventures.
Will Epitel, Inc. IPO soon?
No public IPO plans have been announced for Epitel, Inc..
How can I track Epitel, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Epitel, Inc.'s shares on secondary markets.